Quick Dispatch:
Your tirzepatide surmount trials Tirzepatide not linked to increased risk for depression orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surmount trials Tirzepatide not linked to increased risk for depression ships.
Need Help?
Questions about tirzepatide surmount trials Tirzepatide not linked to increased risk for depression, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surmount trials Tirzepatide not linked to increased risk for depression in your area.
SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants
21.42
00377-2/asset/984f48c3-9a91-4eba-8a7d-d724f5e65288/main.assets/gr2_lrg.jpg)
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
22.22
Tirzepatide Demonstrates Sustained Weight Loss but Discontinuation Results in Weight Regain: SURMOUNT-4 Trial
19.99
In the SURMOUNT-5 trial, Zepbound (tirzepatide) achieved a 20.2% average weight loss over 72 weeks, surpassing Wegovy (semaglutide)'s 13.7%. Additionally, 64.6% of Zepbound users lost at least 15% of their body weight,
26.95
SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide
21.07
Tirzepatide Protocol Training as Medical Weight Loss Treatment
28.17
NICE recommends Lilly's tirzepatide for type 2 diabetes treatment
20.67
